Active, not recruitingPhase 2NCT03474744
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Christian Buske
- Principal Investigator
- Christian Buske, MDUniversity Hospital of Ulm
- Intervention
- Copanlisib(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2027
Study locations (18)
- Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I, Vienna, Austria
- St. Josef-Hospital, Medizinische Klinik I, Bochum, Germany
- Johanniter GmbH, Johanniter-Krankenhaus, Bonn, Germany
- ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing, Dingolfing, Germany
- Kath. Karl-Leisner-Klinikum gGmbH, Betriebsstätte Wilhelm-Anton-Hospital, Goch, Germany
- MVZ Goslar, MVZ Onkologische Kooperation Harz, Goslar, Germany
- Universitätsklinikum Halle, Klinik und Poliklinik für Innere Medizin, Halle, Germany
- Rotes Kreuz Krankenhaus, Klinik für Interdisziplinäre Onkologie, Kassel, Germany
- ÜBAG MVZ Dr. Vehling-Kaiser GmbH, Landshut, Germany
- Gemeinschaftspraxis, Fachärzte für Innere Medizin, Mannheim, Germany
- Universitätsmedizin Mannheim, III. Medizinische Klinik, Mannheim, Germany
- Kliniken Ostalb Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin, Mutlangen, Germany
- Klinikum der Universität München, Medizinische Klinik und Poliklinik III, München, Germany
- Sana Klinikum Offenbach GmbH, Offenbach, Germany
- Universitätsklinik PIUS Hospital, Innere Medizin, Oldenburg, Germany
- +3 more locations on ClinicalTrials.gov
Collaborators
University of Ulm · Optimapharm · X-act Cologne Clinical Research GmbH · Zentrum für Klinische Studien Ulm · Celltrion Healthcare Co., LTD · Bayer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03474744 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07554898Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University